Improved Antithrombotic Activity and Diminished Bleeding Side Effect of a PEGylated αIIbβ3 Antagonist, Disintegrin
Open Access
Abstract
Polymer polyethylene glycol (PEG), or PEGylation of polypeptides improves protein drug stability by decreasing degradation and reducing renal clearance. To produce a pharmaceutical disintegrin derivative, the N-terminal PEGylation technique was used to modify the disintegrin derivative [KGDRR]trimucrin for favorable safety, pharmacokinetic profiles, and antithrombotic efficacy. We compared intact [KGDRR]trimucrin (RR) and PEGylated KGDRR (PEG-RR) by in vitro and in vivo systems for their antithrombotic activities. The activity of platelet aggregation inhibition and the bleeding tendency side effect were also investigated. PEG-RR exhibited optimal potency in inhibiting platelet aggregation of human/mouse platelet-rich plasma activated by collagen or ADP with a lower IC50 than the intact derivative RR. In the illumination-induced mesenteric venous thrombosis model, RR and PEG-RR efficaciously prevented occlusive thrombosis in a dose-dependent manner. In rotational thromboelastometry assay, PEG-RR did not induce hypocoagulation in human whole blood even given at a higher concentration (30 μg/mL), while RR slightly prolonged clotting time. However, RR and PEG-RR were not associated with severe thrombocytopenia or bleeding in FcγRIIa-transgenic mice at equally efficacious antithrombotic dosages. We also found the in vivo half-life of PEGylation was longer than RR (RR: 15.65 h vs. PEG-RR: 20.45 h). In conclusion, injectable PEG-RR with prolonged half-life and decreased bleeding risk is a safer anti-thrombotic agent for long-acting treatment of thrombus diseases.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (MOST 107-2320-B-715-004-MY3)
- Mackay Medical College (MMC-1071B25, MMC-1072B33, and MMC-1081B14)
This publication has 35 references indexed in Scilit:
- Advanced drug delivery systems for antithrombotic agentsBlood, 2013
- Snake Venom Disintegrins and Cell MigrationToxins, 2010
- PEGylation of therapeutic proteinsBiotechnology Journal, 2010
- FcγRII mediates platelet aggregation caused by disintegrins and GPIIb/IIIa monoclonal antibody, AP2Experimental Hematology, 2008
- Coagulation Monitoring: Current Techniques and Clinical Use of Viscoelastic Point-of-Care Coagulation DevicesAnesthesia & Analgesia, 2008
- The highly specific platelet glycoprotein (GP) VI agonist trowaglerix impaired collagen‐induced platelet aggregation ex vivo through matrix metalloproteinase‐dependent GPVI sheddingJournal of Thrombosis and Haemostasis, 2008
- Antithrombotic Effect of a Protein-Type I Class Snake Venom Metalloproteinase, Kistomin, Is Mediated by Affecting Glycoprotein Ib-von Willebrand Factor InteractionMolecular Pharmacology, 2007
- Platelet FcγRIIA binds and internalizes IgG-containing complexesExperimental Hematology, 2006
- PegylationClinical Pharmacokinetics, 2001
- Integrins: Versatility, modulation, and signaling in cell adhesionCell, 1992